Nanexa AB

Equities

NANEXA

SE0007074166

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 11:19:50 2024-05-30 EDT			5-day change	1st Jan Change
1.035 ^SEK	-0.96%		+14.75%	-15.85%

05-15	Nanexa AB Elects Hanna Tilus as Members of the Board	CI
05-15	Nanexa AB Receives Approval for NEX-22 Clinical Study	CI

Nanexa Q1 2024 - Insightful capital markets day

May 10, 2024 at 05:02 am

Redeye updates its view of Nanexa following the Q1 report and recent events in the company, including the CMD earlier this week, which offered a deeper look into the company's several activities.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Nanexa AB

Nanexa AB Elects Hanna Tilus as Members of the Board	05-15	CI
Nanexa AB Receives Approval for NEX-22 Clinical Study	05-15	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	04-16	CI
Transcript : Nanexa AB - Special Call	03-07
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	12-20	CI
Nanexa Signs Feasibility Study Contract for PharmaShell; Shares Jump	11-29	MT
Nanexa AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Nanexa AB Completes Clinical Phase I Study with NEX-20	23-10-05	CI
Nanexa to Raise SEK121 Million via Rights Issue; Shares Drop 5%	23-09-22	MT
Nanexa Gets India Patent for PharmaShell Technology	23-08-30	MT
Nanexa AB Receives Patent in India	23-08-30	CI
Nanexa AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22	23-08-22	CI
Nanexa AB Obtains Pharmacokinetic Data from the NEX-20 Phase 1 Study Confirming Controlled Release of Lenalidomide	23-08-22	CI
Nanexa AB Approves Election of Jakob Dynnes Hansen as Member of the Board	23-06-09	CI
Nanexa Completes Recruitment for Phase 1 Myeloma Cancer Drug Study	23-06-09	MT
Nanexa AB Completes Planned Recruitment to the Phase 1 Study of NEX-20	23-06-09	CI
Nanexa AB Signs Contract with Leading International Diabetes Cro for Phase I Study with Nex-22	23-06-01	CI
Nanexa AB Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election	23-05-10	CI
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Nanexa AB Announces Positive Outcome in the First Preclinical Study with NEX-22	23-03-23	CI
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-16	CI
Nanexa AB announced that it has received SEK 17.2 million in funding from Novo Nordisk A/S	22-12-20	CI

Chart Nanexa AB

Duration

Period

More charts

Company Profile

Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-26 - Q2 2024 Earnings Release

More about the company